权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Advancing precision pain medicines to the clinic

将精准止痛药推向临床

基本信息

批准号：
10822921
负责人：
Fernando Aleman Guillen
金额：
$ 40万
依托单位：
NAVEGA THERAPEUTICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-22 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10822921
关键词：
Acute Pain Affect Analgesics Animal Model Antibodies Binding Budgets Businesses CRISPR/Cas technology Carrageenan Chemotherapy-induced peripheral neuropathy Clinic Congenital Pain Insensitivity DNA Dependovirus Development Diabetes Mellitus Drug Kinetics Economic Burden Elderly Ensure Epigenetic Process Erythromelalgia Failure Fiber Freund&apos s Adjuvant Genome Goals Grant Guide RNA K/BxN model Leadership Medicine Methods Modeling Molecular Conformation Mus Mutation Neurons Neuropathy Nociception Opioid Pain Pain management Patients Persistent pain Persons Pharmaceutical Preparations Pharmacologic Substance Population Pre-Clinical Model Prevalence Proteins Quality of life RNA Rare Diseases Repression Rheumatoid Arthritis Risk Societies Sodium Channel Specificity Spinal Ganglia Survival Rate System Therapeutic Time Transcription Repressor Translating Variant Zinc Fingers addiction alternative treatment cancer survival central pain chronic pain chronic pain management chronic pain patient clinical development design drug development efficacious treatment epigenome gain of function mutation gene therapy healing improved inflammatory pain innovation intense pain interest loss of function meetings novel novel therapeutics opioid epidemic pain model pain reduction pain relief prescription opioid prevent programs side effect small molecule inhibitor socioeconomics

项目摘要

Abstract Chronic pain is pain that persists past the normal time of healing. 1.5 billion people worldwide suffer from chronic pain and this number continues to increase as the elderly population grows, the prevalence of diabetes rises, and cancer survival rates improve. Chronic pain not only severely impacts daily quality of life for many patients, it also places a heavy socioeconomic burden on society. Due to the limited number of efficacious treatment options available, chronic pain is often treated with opioids despite the risk of addiction and side effects. Unfortunately, the prescribing of opioids to treat chronic pain has largely fueled the current opioid epidemic. Therefore, there is an urgent and clear unmet need for non-addictive alternative analgesics for the treatment of chronic pain. The push to develop specific and non-addictive alternative painkillers has brought interest to a particular sodium channel, NaV1.7, shown to be important for pain sensing. Gain-of-function mutations in NaV1.7 are associated with rare disorder characterized by intense pain, such as in patients with primary erythromelalgia and small-fiber neuropathy. Additionally, NaV1.7 expression levels have been shown to increase in various pain conditions. Conversely, loss-of function of NaV1.7 results in the inability to feel pain. Therefore, inhibiting NaV1.7 can be an effective method of reducing pain and treating patients with chronic pain. To accomplish this, we designed epigenetic modulators to repress expression of NaV1.7. Rather than making permanent edits to the genome, these epigenetic modulators will transiently inhibit expression of NaV1.7. By targeting NaV1.7 at the DNA-level, we can achieve specific and long-lasting modulation of NaV1.7, with better pharmacokinetics prospects than RNA- and protein- targeting approaches. This innovative approach has been shown to prevent and reverse acute and chronic pain in five preclinical models of pain. Given the exciting novelty of this approach, in addition to its high level of specificity and efficacy, the goal of this project is to support the business development activities in finding a strong partner to bring this therapy to the millions of patients that need non-addictive, efficacious, and long-lasting treatments for chronic pain.

摘要